FIELD: biotechnology.
SUBSTANCE: disclosed are a humanized antibody against the IGF-1 receptor, or a fragment thereof, or a derivative thereof, as well as pharmaceutical compositions containing them. Invention also relates to a nucleic acid encoding said antibody, vectors and cells containing said nucleic acid, a method of producing the antibody.
EFFECT: invention can find further application in therapy of IGF-1 receptor related diseases.
30 cl, 15 dwg, 17 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| METHODS OF PREVENTING AND TREATING HEART DISEASES | 2018 |
|
RU2830232C2 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2838943C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
